Teladoc Health (NYSE:TDOC) Posts Earnings Results, Beats Estimates By $0.03 EPS

Teladoc Health (NYSE:TDOC) issued its quarterly earnings results on Wednesday. The health services provider reported ($0.21) earnings per share for the quarter, topping the consensus estimate of ($0.24) by $0.03, Zacks reports. Teladoc Health had a negative net margin of 6.81% and a negative return on equity of 11.45%. Teladoc Health updated its Q3 2026 guidance to -0.300–0.200 EPS and its FY 2026 guidance to -1.000–0.750 EPS.

Teladoc Health Trading Down 1.6%

Teladoc Health stock traded down $0.15 during trading on Wednesday, reaching $9.21. 7,121,675 shares of the company were exchanged, compared to its average volume of 5,388,957. The stock’s 50 day simple moving average is $8.16 and its two-hundred day simple moving average is $6.54. The company has a market capitalization of $1.66 billion, a P/E ratio of -9.50 and a beta of 2.10. Teladoc Health has a 52-week low of $4.40 and a 52-week high of $9.89. The company has a debt-to-equity ratio of 0.75, a current ratio of 2.80 and a quick ratio of 2.72.

Key Stories Impacting Teladoc Health

Here are the key news stories impacting Teladoc Health this week:

• Positive Sentiment: Teladoc reported a second-quarter loss of $0.21 per share, better than analysts’ expected loss of $0.24. The earnings beat may support confidence in the company’s cost controls and near-term execution. Teladoc Health Reports Second Quarter 2026 Results
• Positive Sentiment: A valuation analysis argued that TDOC remains undervalued after its severe five-year decline, with discounted-cash-flow and market-multiple estimates indicating potential upside. This could attract value-oriented investors, although it is not a formal company forecast. Teladoc Health Stock Still Looks Undervalued
• Neutral Sentiment: Teladoc’s second-quarter results and accompanying materials provide investors with additional detail on operating metrics and management’s outlook. The earnings release itself did not eliminate concerns about the company’s longer-term path to profitability. Teladoc Health Earnings Slide Deck
• Negative Sentiment: Third-quarter guidance was below Wall Street expectations. Teladoc forecast an adjusted loss of $0.20–$0.30 per share versus a consensus loss of $0.17, while revenue guidance of $569 million–$609 million trailed the $629.1 million consensus estimate.
• Negative Sentiment: Full-year 2026 revenue guidance of approximately $2.4 billion was below the $2.5 billion analyst estimate. The company also remains unprofitable, reporting a negative 6.81% net margin and negative 11.45% return on equity.
• Negative Sentiment: A law firm issued a shareholder-investigation solicitation concerning possible fiduciary-duty issues involving Teladoc insiders. While unproven and promotional in nature, such announcements can add headline and litigation risk.

Analyst Ratings Changes

Several brokerages recently commented on TDOC. Citigroup increased their price objective on shares of Teladoc Health from $6.00 to $7.00 and gave the company a “neutral” rating in a research note on Tuesday, May 5th. Weiss Ratings upgraded Teladoc Health from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Friday, May 22nd. Canaccord Genuity Group lifted their price target on shares of Teladoc Health from $10.00 to $11.00 and gave the stock a “buy” rating in a research note on Tuesday, July 21st. Finally, Bank of America lifted their price target on Teladoc Health from $9.00 to $10.50 and gave the company a “buy” rating in a research report on Tuesday, July 7th. Five research analysts have rated the stock with a Buy rating, ten have given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, Teladoc Health currently has a consensus rating of “Hold” and a consensus price target of $7.57.

Insider Activity

In other Teladoc Health news, insider Carlos Nueno sold 6,196 shares of the stock in a transaction dated Tuesday, June 2nd. The shares were sold at an average price of $7.63, for a total value of $47,275.48. Following the completion of the transaction, the insider directly owned 57,671 shares of the company’s stock, valued at approximately $440,029.73. This trade represents a 9.70% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO Charles Divita III sold 19,132 shares of Teladoc Health stock in a transaction that occurred on Tuesday, June 2nd. The stock was sold at an average price of $7.63, for a total transaction of $145,977.16. Following the completion of the sale, the chief executive officer directly owned 389,894 shares of the company’s stock, valued at $2,974,891.22. The trade was a 4.68% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold 39,195 shares of company stock worth $299,058 over the last three months. Insiders own 0.70% of the company’s stock.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of TDOC. IFP Advisors Inc raised its stake in shares of Teladoc Health by 412.1% during the third quarter. IFP Advisors Inc now owns 3,989 shares of the health services provider’s stock valued at $31,000 after purchasing an additional 3,210 shares in the last quarter. PNC Financial Services Group Inc. raised its stake in shares of Teladoc Health by 177.7% in the 4th quarter. PNC Financial Services Group Inc. now owns 4,391 shares of the health services provider’s stock valued at $31,000 after buying an additional 2,810 shares in the last quarter. Van ECK Associates Corp grew its position in Teladoc Health by 101.4% during the 4th quarter. Van ECK Associates Corp now owns 9,150 shares of the health services provider’s stock worth $64,000 after acquiring an additional 4,607 shares during the last quarter. Johnson Financial Group Inc. lifted its position in Teladoc Health by 41,045.8% during the 3rd quarter. Johnson Financial Group Inc. now owns 9,875 shares of the health services provider’s stock valued at $76,000 after purchasing an additional 9,851 shares during the period. Finally, Cibc World Markets Corp acquired a new stake in Teladoc Health during the 4th quarter worth $82,000. 76.82% of the stock is currently owned by institutional investors.

About Teladoc Health

Teladoc Health, Inc is a leading global provider of virtual healthcare services, offering on-demand medical consultations via phone, video, and mobile app platforms. The company connects patients with licensed physicians and specialists for non-emergency medical issues, mental health support, dermatology, and chronic condition management. By leveraging digital technologies and data analytics, Teladoc aims to enhance accessibility, reduce healthcare costs, and improve patient outcomes through personalized care plans and remote monitoring.

Teladoc’s service portfolio includes general medical visits, behavioral health sessions, expert medical services for complex cases, and wellness programs designed to support chronic disease management such as diabetes, hypertension, and heart disease.